These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17218138)

  • 1. Determination and analysis of the DNA sequence of highly attenuated herpes simplex virus type 1 mutant HF10, a potential oncolytic virus.
    Ushijima Y; Luo C; Goshima F; Yamauchi Y; Kimura H; Nishiyama Y
    Microbes Infect; 2007 Feb; 9(2):142-9. PubMed ID: 17218138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Oncolytic virotherapy using replication-competent herpes simplex viruses].
    Nishiyama Y; Goshima F
    Uirusu; 2007 Jun; 57(1):57-65. PubMed ID: 18040155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequence of a fusogenic herpes simplex virus, RH2, for oncolytic virotherapy.
    Takahashi G; Meshii N; Hamada M; Iwai S; Yura Y
    J Gen Virol; 2013 Apr; 94(Pt 4):726-737. PubMed ID: 23239570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10.
    Watanabe D; Goshima F; Mori I; Tamada Y; Matsumoto Y; Nishiyama Y
    J Dermatol Sci; 2008 Jun; 50(3):185-96. PubMed ID: 18226503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequence variability in clinical and laboratory isolates of herpes simplex virus 1 reveals new mutations.
    Szpara ML; Parsons L; Enquist LW
    J Virol; 2010 May; 84(10):5303-13. PubMed ID: 20219902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer.
    Kohno S; Luo C; Goshima F; Nishiyama Y; Sata T; Ono Y
    Urology; 2005 Nov; 66(5):1116-21. PubMed ID: 16286150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice.
    Takakuwa H; Goshima F; Nozawa N; Yoshikawa T; Kimata H; Nakao A; Nawa A; Kurata T; Sata T; Nishiyama Y
    Arch Virol; 2003 Apr; 148(4):813-25. PubMed ID: 12664303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of a novel foreign gene delivery system combining an HSV amplicon with an attenuated replication-competent virus, HSV-1 HF10.
    Zhang L; Daikoku T; Ohtake K; Ohtsuka J; Nawa A; Kudoh A; Iwahori S; Isomura H; Nishiyama Y; Tsurumi T
    J Virol Methods; 2006 Nov; 137(2):177-83. PubMed ID: 16854473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Mutation in the
    Dridi S; Richerioux N; Gonzalez Suarez CE; Vanharen M; Sanabria-Solano C; Pearson A
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30068651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
    Kohno SI; Luo C; Nawa A; Fujimoto Y; Watanabe D; Goshima F; Tsurumi T; Nishiyama Y
    Cancer Gene Ther; 2007 Nov; 14(11):918-26. PubMed ID: 17693992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer.
    Goshima F; Esaki S; Luo C; Kamakura M; Kimura H; Nishiyama Y
    Int J Cancer; 2014 Jun; 134(12):2865-77. PubMed ID: 24265099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10.
    Teshigahara O; Goshima F; Takao K; Kohno S; Kimata H; Nakao A; Nishiyama Y
    J Surg Oncol; 2004 Jan; 85(1):42-7. PubMed ID: 14696086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of the herpes simplex virus UL24 gene for productive ganglionic infection in mice.
    Jacobson JG; Chen SH; Cook WJ; Kramer MF; Coen DM
    Virology; 1998 Mar; 242(1):161-9. PubMed ID: 9501052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletion of the S component inverted repeat sequence c' and the nonessential genes U(S)1 through U(S)5 from the herpes simplex virus type 1 genome substantially impairs productive viral infection in cell culture and pathogenesis in the rat central nervous system.
    Rasty S; Poliani PL; Fink DJ; Glorioso JC
    J Neurovirol; 1997 Aug; 3(4):247-64. PubMed ID: 9291233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I Dose-escalation Clinical Trial of HF10 Oncolytic Herpes Virus in 17 Japanese Patients with Advanced Cancer.
    Kasuya H; Kodera Y; Nakao A; Yamamura K; Gewen T; Zhiwen W; Hotta Y; Yamada S; Fujii T; Fukuda S; Tsurumaru N; Kuwahara T; Kikumori T; Koide Y; Fujimoto Y; Nakashima T; Hirooka Y; Shiku H; Tanaka M; Takesako K; Kondo T; Aleksic B; Kawashima H; Goto H; Nishiyama Y
    Hepatogastroenterology; 2014 May; 61(131):599-605. PubMed ID: 26176043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials.
    Eissa IR; Naoe Y; Bustos-Villalobos I; Ichinose T; Tanaka M; Zhiwen W; Mukoyama N; Morimoto T; Miyajima N; Hitoki H; Sumigama S; Aleksic B; Kodera Y; Kasuya H
    Front Oncol; 2017; 7():149. PubMed ID: 28770166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replication-Competent Controlled Herpes Simplex Virus.
    Bloom DC; Feller J; McAnany P; Vilaboa N; Voellmy R
    J Virol; 2015 Oct; 89(20):10668-79. PubMed ID: 26269179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Syn strains HSZP and ANGpath [correction of ANG] of herpes simplex virus type 1 do not contain mutations in the regions of UL53 gene relevant to syncytium formation.
    Kúdelová M; Vojvodová A; Rajcáni J
    Acta Virol; 1998 Feb; 42(1):41-5. PubMed ID: 9645242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Herpes simplex virus type 1 gK is required for gB-mediated virus-induced cell fusion, while neither gB and gK nor gB and UL20p function redundantly in virion de-envelopment.
    Melancon JM; Luna RE; Foster TP; Kousoulas KG
    J Virol; 2005 Jan; 79(1):299-313. PubMed ID: 15596825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.